The most negative interaction was the one found between known antagonists BRAF and NRAS in melanoma (Curtin et al., 2005), while the most positive interactions included those between AURKA gain, APC and TP53 mutations in colorectal cancer (Figure 2d). This evidence concerns the gene NRAS and colorectal cancer.